GRAVITI Patient Fact Sheet

EXPLORE RESEARCH OPTIONS FOR CROHN'S DISEASE

Consider participating in a Crohn's disease clinical trial

Janssen is currently conducting clinical trials for people with Crohn's disease because there is still a need to find treatments that work for everyone. The good news is that we can continue to make progress and potentially find options through clinical research. Let's do it together.

About the **GRAVITI Study**

The purpose of the **GRAVITI Study** is to evaluate the safety and efficacy of an investigational medication compared with placebo in adults with moderately to severely active Crohn's disease.

You may be able to take part in the **GRAVITI Study** if you:

- Ð
- Are 18 years of age or older
- Have had a diagnosis of Crohn's disease or fistulizing Crohn's disease for at least 3 months
- Are currently experiencing a reappearance or worsening of your Crohn's disease symptoms, called a flare, which may include:
 - Frequent and/or urgent bowel movements
 - Abdominal pain
 - Lack of appetite
 - Diarrhea

Are been unsuccessful with previous medications to treat your Crohn's disease

Additional eligibility criteria will be assessed by the trial doctor or staff.

FAQS

What's involved with participation in the GRAVITI Study?

Participants will receive an investigational medication or placebo while completing various tests and procedures.

The trial consists of four phases:

- Screening Phase (up to 5 weeks)
- Main Treatment Phase (24 weeks)
- Extension Treatment Phase (72 weeks)
- Post-Treatment Phase (12 weeks; starts after the last dose of trial medication)

Participation in the **GRAVITI Study** is expected to last up to 109 weeks (around 2 years)

Participation includes visits to the trial clinic about every 4 weeks. After Week 48, participants may have the option to do the trial visits via telemedicine contact (e.g., by video call) at every other visit starting at Week 52

Is there a placebo in this trial?

Yes, there is a placebo in this trial. A placebo is an inactive substance that seems identical to the investigational medication being tested, and it is used to help determine the safety and efficacy of the investigational medication being studied compared to the absence of the investigational medication.

Does participating in this trial cost anything?

All trial-required visits, tests, and medications are provided at no cost to qualified participants. The trial will not pay for other medical care or current medication(s) needed to support your daily healthcare routine. In addition, reimbursement for trial-required travel, meals, and parking may be available.

If prequalified, what can I expect on my first visit to the trial clinic?

This initial appointment is an opportunity for you to:

- Ask any important questions you may have. These can be any questions you may have about this trial or clinical trials in general.
- Determine if the GRAVITI Study may be right for you. You will speak with a trial coordinator and learn more about the trial. The trial coordinator will ask you about your health history to determine if you are eligible for the trial. If you are eligible, you will be given the opportunity to decide if participation is right for you. If you agree to take part, you will be asked to review and sign a consent form for trial participation. Once you have signed the trial consent form, the research staff will perform a series of tests to determine if you are right for the trial and if the trial is right for you. Even if you decide to participate, you can leave the trial at any time.

What if my condition worsens or I have side effects?

You will be closely monitored while participating in the trial, and you should make sure to inform your doctor of any new symptoms you experience.

Where are the trial clinics located?

There are trial clinics located around the world. Find a location near you by visiting weknowibd.com/current-trials.html.

See if the GRAVITI Study is right for you.



weknowibd.com/about-the-graviti-study.htm



Janssen Research & Development, LLC CNTO1959CRD3004_ENG30 Version 1.0, 03Sept2021

